Practitioner's Guide
How to Source Exosomes for Your Clinic: A Practitioner's Guide
The exosome supply market is uneven. Not all products are equally characterized, and not all COAs tell the full story. This guide covers what analytical characterization to require, how to read an exosome COA, and the red flags that signal a supplier you should avoid.
Written by Benn Bluestein-Veyra, M.Sc. Organic Chemistry Founder, ExaVeyra Sciences
The ExaBlog
New: The science behind exosomes in aesthetic medicine clinical trials, MSC sourcing, and honest caveats.
What You're Actually Buying
Exosomes are nano-sized extracellular vesicles 30 to 150 nanometers in diameter secreted by cells as a primary mechanism of intercellular communication. When derived from mesenchymal stem cells (MSCs), they carry a cargo of growth factors, cytokines, mRNA, microRNA, and signaling proteins that instruct recipient cells to reduce inflammation, proliferate, and regenerate tissue.
But "exosomes" is also a loosely applied marketing term. In the supply market, products labeled as exosomes range from rigorously characterized MSC-derived preparations with HPLC, RNA quantification assay, and NanoSight NTA documentation, to poorly defined cell culture supernatants with minimal quality control. The difference between these products is significant clinically and commercially and a COA alone does not tell the whole story.
Understanding what questions to ask, what data to require, and what characterization standards define a quality exosome preparation is the foundation of responsible sourcing. This guide gives you that framework.
Analytical Characterization, Not Marketing Counts
Headline particle counts (particles per mL or per vial) are commonly used in exosome marketing but vary widely by supplier, format, and lot. They should not be treated as a standalone product specification. What matters is documented analytical methodology on the lot-specific COA.
ExaVeyra distributes Kimera Labs biomolecular signaling vesicles characterized by HPLC, RNA quantification assay, and NanoSight NTA, confirming exosome identity and formulation integrity. Products are cell-free topical cosmetic formulations from perinatal MSCs with proteins, enzymes, growth factors, and exosomes—single donor placental source, no animal or human serum.
When evaluating any supplier, review NanoSight NTA size distribution (a predominant peak between 50 and 150 nanometers), disclosed instrument methodology, and supporting HPLC and RNA quantification data. Preparations with broad distributions, secondary peaks above 200nm, or no analytical documentation should prompt follow-up questions before ordering.
What to Require on the COA
- HPLC characterization documentation
- RNA quantification assay documentation
- NanoSight NTA size peak: 50-150nm with methodology disclosed
- Mode and mean size reported where applicable
- Sterility, endotoxin, and mycoplasma results per lot
Kimera Labs Characterization Standards
ExaVeyra catalog exosomes are manufactured and characterized by Kimera Labs using documented analytical methods: HPLC, ELISA where applicable, RNA quantification assay, NanoSight NTA, atomic force microscopy (AFM), electron microscopy, and STORM fluorescence microscopy.
These methods confirm formulation composition—proteins, enzymes, growth factors, and exosomes from perinatal MSCs—in a cell-free topical cosmetic formulation. Practitioners should review the lot-specific COA for the analytical package provided with each release, not marketing summaries.
A supplier that cannot provide HPLC, RNA quantification, and NanoSight NTA documentation for the specific lot you are ordering has not met the baseline standard ExaVeyra applies before onboarding a product.
HPLC
Chromatographic characterization of formulation components and integrity.
RNA Quantification
Assay-based quantification supporting vesicle cargo documentation.
NanoSight NTA
Size-distribution characterization with disclosed instrument methodology.
Exosome COA Checklist What to Require
Before placing your first order with any exosome supplier, request a sample COA and verify it includes the following. Critical items are non-negotiable for clinical sourcing.
Red Flags When to Walk Away
The following are warning signs that a supplier's product quality or documentation standards are insufficient for clinical sourcing.
Liquid Exosome Formulations: Logistics & Quality
Many high-characterization exosome products are distributed as sterile liquid suspensions. That choice prioritizes native vesicle handling and ready-to-use workflows, but it places responsibility on cold-chain execution and documented temperature monitoring.
Liquid exosomes generally require cold-chain shipping at 2–8°C and refrigerated storage per the manufacturer and COA. Post-receipt shelf life is formulation- and lot-dependent. Temperature excursions during transit can affect biological activity without obvious visual change—validate partner logistics and data loggers when evaluating suppliers.
ExaVeyra Sciences supplies exosomes as advanced liquid MSC-derived formulations with cold-chain support. When comparing suppliers, read the COA for storage, shipping, and stability claims for the specific lot you intend to order.
How ExaVeyra Sciences Evaluates Exosome Suppliers
At ExaVeyra Sciences, every exosome product in our catalog is evaluated by our founder an M.Sc. organic chemist with expertise in analytical chemistry, synthetic chemistry, and biochemistry. We apply the same analytical rigor to supplier evaluation that we applied in the laboratory: methodology matters as much as the reported result.
Our evaluation process covers HPLC and RNA quantification assay documentation, NanoSight NTA data and instrument methodology, sterility and endotoxin testing methodology, manufacturing facility registration and cGMP compliance documentation, cold-chain handling protocols, and lot-to-lot consistency data. We do not onboard suppliers who cannot provide complete characterization documentation.
For our wholesale partners, we provide lot numbers and COA documentation with every order and can provide the underlying characterization data on request. Our supply chain is designed for practitioner confidence not just product delivery.
Exosome Sourcing FAQ
- What characterization data should a quality exosome COA include?
- For ExaVeyra catalog products, Kimera Labs biomolecular signaling vesicles are characterized by HPLC, RNA quantification assay, and NanoSight NTA, confirming exosome identity and formulation integrity. A quality COA should also include sterility testing results, endotoxin (LAL) test results, mycoplasma testing, and lot number with manufacturing date. When evaluating any supplier, request lot-specific methodological data—not marketing particle-count figures alone.
- What is NanoSight NTA and why does it matter for exosome quality?
- NanoSight NTA tracks individual particle Brownian motion under laser illumination to report size distribution. A quality preparation should show a predominant peak between 50-150nm with disclosed instrument methodology. Preparations with broad distributions, secondary peaks above 200nm, or no NTA data at all should prompt follow-up questions before ordering.
- How are liquid exosome formulations handled in practice?
- Liquid exosome preparations typically ship on cold-chain (2–8°C) and are stored refrigerated per the manufacturer and COA. Shelf life and handling steps are lot-specific. Some suppliers market freeze-dried exosomes for ambient logistics; ExaVeyra's exosome catalog is supplied as advanced liquid MSC-derived formulations—always confirm format, stability, and reconstitution instructions on the COA before use.
- What red flags should I watch for when evaluating an exosome supplier?
- Red flags include: no NTA methodology or size-distribution data (only a headline particle count), no HPLC or RNA quantification documentation, no sterility or endotoxin test data, no lot numbers, inability to provide COA on request, claims of 'stem cell exosomes' without specifying cell source, no information about manufacturing facility registration, and pricing that seems too good to be true relative to verified cGMP suppliers.
- Are exosomes regulated by the FDA?
- MSC-derived exosomes occupy a complex regulatory space. They are generally classified as biological products under FDA jurisdiction rather than as compounded drugs. The FDA has issued guidance indicating that many exosome products intended for clinical use would require IND (Investigational New Drug) applications or BLA (Biologics License Application) pathways. Clinics should work with suppliers who provide full manufacturing documentation and stay current on FDA guidance in this rapidly evolving area.
- How does ExaVeyra Sciences verify exosome quality before supplying to clinics?
- Our founder—an M.Sc. organic chemist with a background in analytical chemistry—reviews manufacturing documentation, HPLC and RNA quantification assay data, NanoSight NTA methodology, sterility and endotoxin testing, and stability data for every exosome product in our catalog. We evaluate the analytical methodology behind the COA, not just the summary document. Products that cannot provide complete characterization data do not enter our supply chain.
Related Resources
Exosome Product Catalog
Browse MSC-derived exosome vials and companion biologics; specifications on each COA.
Read →503A vs 503B Guide
Understand compounding regulatory frameworks and which applies to your clinic sourcing.
Read →Exosomes & Aesthetic Medicine
Peer-reviewed deep dive: MSC sourcing, 292 registered clinical trials, and the science behind the buzz.
Read →Apply for Wholesale Access
Apply for NPI-verified access to our full exosome catalog with COA and lot tracking.
Read →Source Exosomes You Can Trust
ExaVeyra supplies licensed clinics with Kimera Labs biomolecular signaling vesicles characterized by HPLC, RNA quantification assay, and NanoSight NTA— reviewed by an M.Sc. organic chemist. Full COA and lot tracking on every order.